Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PLD plus carboplatin in gynecologic sarcomas and mixed epithelial-mesenchymal tumors
2008-000245-55Phase 2Completed
- Sponsor
- GYN Research
- Start
- Apr 2008
- Modality
- Small Molecules, Liposomes → Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pegylated liposomal doxorubicin in gynaecological sarcoma and mixed epithelial-mesenchymal tumor of the gynecologic tract, sponsored by GYN Research. Primary endpoint: Progression-free survival after six cycles of chemotherapy. Started Apr 2008; status: completed.
02
Drugs
pegylated liposomal doxorubicin
03
Conditions
gynaecological sarcomamixed epithelial-mesenchymal tumor of the gynecologic tract
Beyond the preview
Go deeper on 2008-000245-55.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-000245-55.